Molecular epidemiology of HIV in two highly endemic areas of northeastern South Africa

Archives of Virology

Volumn 157, Issue 3, 2012, Pages 455-465

  Iweriebor, Benson Chuks ^a   Mavhandu, Lufuno Grace ^a   Masebe, Tracy ^a   Rekosh, David ^b   Hammarskjold, Marie Louise ^b   Mphahlele, Jeffrey M ^c   Bessong, Pascal Obong ^a  

^a UNIVERSITY OF VENDA   (South Africa)

^b UNIVERSITY OF VIRGINIA   (United States)

^c SEFAKO MAKGATHO HEALTH SCIENCES UNIVERSITY   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

VIRUS PROTEIN; VIRUS RNA;

ADULT; AMINO ACID SUBSTITUTION; ARTICLE; CHILD; CLASSIFICATION; CLUSTER ANALYSIS; DNA SEQUENCE; FEMALE; GENETIC VARIABILITY; GENETICS; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; ISOLATION AND PURIFICATION; MALE; MIDDLE AGED; MISSENSE MUTATION; MOLECULAR EPIDEMIOLOGY; MOLECULAR GENETICS; NUCLEOTIDE SEQUENCE; PHYLOGENY; PREVALENCE; SOUTH AFRICA; VIROLOGY;

ADULT; AMINO ACID SUBSTITUTION; CHILD; CLUSTER ANALYSIS; FEMALE; GENETIC VARIATION; GENOTYPE; HIV INFECTIONS; HIV-1; HUMANS; MALE; MIDDLE AGED; MOLECULAR EPIDEMIOLOGY; MOLECULAR SEQUENCE DATA; MUTATION, MISSENSE; PHYLOGENY; PREVALENCE; RNA, VIRAL; SEQUENCE ANALYSIS, DNA; SOUTH AFRICA; VIRAL PROTEINS;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 84857801866     PISSN: 03048608     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00705-011-1180-z     Document Type: Article

References (45)

1. Moore MD, Hu WS (2009) HIV-1 RNA dimerization: It takes two to tango. AIDS Rev 11(2): 91-102.
2. Onafuwa-Nuga A, Telesnitsky A (2009) The remarkable frequency of human immunodeficiency virus type 1 genetic recombination. Microbiol Mol Biol Rev 73(3): 451-480.
3. Simon-Loriere E, Rossolillo P, Negroni M (2011) RNA structures, genomic organization and selection of recombinant HIV. RNA Biol 8(2): 280-286.
4. Powell RL, Zhao J, Konings FA et al (2007) Circulating recombinant form (CRF) 37_cpx: an old strain in Cameroon composed of diverse, genetically distant lineages of subtypes A and G. AIDS Res Hum Retroviruses 23(7): 923-933.
5. Brennan CA, Brites C, Bodelle P et al (2007) HIV-1 strains identified in Brazilian blood donors: significant prevalence of B/F1 recombinants. AIDS Res Hum Retroviruses 23(11): 1434-1441.
6. Gao F, Vidal N, Li Y et al (2001) Evidence of two distinct subsubtypes within the HIV-1 subtype A radiation. AIDS Res Hum Retroviruses 17(8): 675-688.
7. van der Auwera G, Janssens W, Heyndrickx L et al (2001) Reanalysis of full-length HIV type 1 group M subtype K and sub-subtype F2 with an MS-DOS bootscanning program. AIDS Res Hum Retroviruses 17(2): 185-189.
8. Castelbranco EP, da Silva Souza E, Cavalcanti AM et al (2010) Frequency of primary resistance to antiretroviral drugs and genetic variability of HIV-1 among infected pregnant women recently diagnosed in Luanda-Angola. AIDS Res Hum Retroviruses 26(12): 1313-1316.
9. Hemelaar J, Gouws E, Ghys PD et al (2011) Global trends in molecular epidemiology of HIV-1 during 2000-2007. AIDS 25: 679-689.
10. Department of Health (2004) National HIV Seroprevalence survey of women attending antenatal clinics in South Africa. Directorate Health System Research and Epidemiology. Department of Health, Pretoria.
11. Williamson C, Englebrecht S, Lambrick M et al (1995) HIV-1 subtypes in different risk groups in South Africa. Lancet 346: 782.
12. Gordon M, De Oliveria T, Bishop K et al (2003) Molecular characterization of human immunodeficiency virus type 1 subtype C viruses from KwaZulu-Natal, South Africa: implication for vaccine and antiretroviral control strategies. J Virol 77: 2587-2599.
13. Jacobs GB, Laten AD, van Rensburg EJ et al (2008) Phylogenetic diversity and low level antiretroviral resistance mutations in HIV Type 1 treatment-naive patients from Cape Town, South Africa. AIDS Res Hum Retroviruses 24: 1009-1012.
14. Hemelaar J, Gouws E, Ghys PD et al (2006) Global and regional distribution of HIV-1 genetic subtypes and recombinants in 2004. AIDS 20: W13-W23.
15. Bredell H, Hunt G, Casteling A et al (2002) HIV-1 subtypes A, D, G, AG and unclassified sequences identified in South Africa. AIDS Res Hum Retroviruses 18: 681-683.
16. Papathanasopoulos MA, Vardas E, Wallis C et al (2010) Characterization of HIV type 1 genetic diversity among South African participants enrolled in the AIDS Vaccine Integrated Project (AVIP) study. AIDS Res Hum Retroviruses 26: 705-709.
17. Peeters M, Sharp PM (2000) Genetic diversity of HIV-1: the moving target. AIDS 14(Suppl 3): S129-S140.
18. Lal RB, Sekher C, Chunfu Y (2005) Impact of genetic diversity of HIV-1 on diagnosis, antiretroviral therapy & vaccine development. Indian J Med Res 121: 287-314.
19. Bredell H, Williamson C, Sonnenberg P et al (1998) Genetic characterization of HIV type 1 from migrant workers in three South African gold mines. AIDS Res Hum Retroviruses 14: 677-684.
20. Pillay C, Bredell H, McIntyre J et al (2002) HIV-1 subtype C reverse transcriptase sequences from drug naive pregnant women in South Africa. AIDS Res Hum Retroviruses 18: 605-610.
21. Bessong PO, Obi CL, Cilliers T et al (2005) Characterization of human immunodeficiency virus type 1 from a previously unexplored region of South Africa with a high HIV prevalence. AIDS Res Hum Retroviruses 21(1): 103-109.
22. Bessong PO, Mphahlele J, Choge IA et al (2006) Resistance mutational analysis of HIV-1 subtype C among rural South African drug-naïve patients prior to large-scale availability of antiretrovirals. AIDS Res Hum Retroviruses 22(12): 1306-1312.
23. UNAIDS AIDS epidemic update (2010). Geneva.
24. Department of Health (2010) National Antenatal Sentinel HIV and Syphilis Prevalence Survey in South Africa, 2009.
25. Jacobs GB, Loxton AG, Laten A et al (2009) Emergence and diversity of different HIV-1 subtypes in South Africa, 2000-2001. J Med Virol 81(11): 1852-1859.
26. Naidoo AF, Parboosing R, Gordon ML (2009) Dual HIV infection uncommon in patients on antiretroviral therapy in a region with high HIV prevalence. AIDS Res Hum Retroviruses 25(12): 1225-1230.
27. Papathanasopoulos MA, Vardas E, Wallis C et al (2010) Characterization of HIV type 1 genetic diversity among South African participants enrolled in the AIDS Vaccine Integrated Project (AVIP) study. AIDS Res Hum Retroviruses 26(6): 705-709.
28. Bussmann H, Novitsky V, Wester W et al (2005) HIV-1 subtype C drug-resistance background among ARV-naive adults in Botswana. Antivir Chem Chemother 16(2): 103-115.
29. Bártolo I, Casanovas J, Bastos R et al (2009) HIV-1 genetic diversity and transmitted drug resistance in health care settings in Maputo, Mozambique. J Acquir Immune Defic Syndr 51(3): 323-331.
30. zur Megede J, Engelbrecht S, de Oliveira T et al (2002) Novel evolutionary analyses of full-length HIV type 1 subtype C molecular clones from Cape Town, South Africa. AIDS Res Hum Retroviruses 18(17): 1327-1332.
31. Bredell H, Martin DP, van Harmelen J et al (2007) HIV type 1 subtype C gag and nef diversity in Southern Africa. AIDS Res Hum Retroviruses 23(3): 477-481.
32. Velaqueze-Campoy A, Todd MJ, Vega S et al (2001) Catalytic efficiency and vitality of HIV-1 protease from African viral subtype. Proc Natl Acad Sci USA 98: 6062-6067.
33. Soriano V, de Mendoza C (2002) Genetic mechanisms of resistance to protease inhibitors and entry inhibitors. HIV Clin Trials 3: 249-257.
34. Kantor R, Katzenstein D (2003) Polymorphism in HIV-1 non-subtype B protease and reverse transcriptase and its potential impact on drug susceptibility and drug resistance evolution. AIDS Rev 5: 25-35.
35. Holguin L, Paxinos E, Hertogs K et al (2004) Impact of frequent natural polymorphisms at the protease gene on the in vitro susceptibility to protease inhibitor in HIV-1 non-B subtypes. J Clin Virol 31: 215-220.
36. Wainberg MA (2004) HIV-1 subtypes distribution and the problem of drug resistance. AIDS 18(suppl 3): S63-S68.
37. Parreira R, Piedade J, Domingues A et al (2006) Genetic characterization of human immunodeficiency virus type 1 from Beira, Mozambique. Microbes Infect 8: 2442-2451.
38. Sayana S, Khanlou H (2009) Maraviroc: a new CCR5 antagonist. Expert Rev Anti Infect Ther 7(1): 9-19.
39. Reuter S, Braken P, Jensen B et al (2010) Maraviroc in treatment-experienced patients with HIV-1 infection-experience from routine clinical practice. Eur J Med Res 15(6): 231-237.
40. Vandekerckhove L, Verhofstede C, Demecheleer E et al (2011) Comparison of phenotypic and genotypic tropism determination in triple-class-experienced HIV patients eligible for maraviroc treatment. J Antimicrob Chemother 66(2): 265-272.
41. Tscherning C, Alaeus A, Fredriksson R et al (1998) Differences in chemokine coreceptor usage between genetic subtypes of HIV-1. Virology 241: 181-188.
42. Thomson MM, Perez-Alvarez L, Najera R (2002) Molecular epidemiology of HIV-1 genetic forms and its significance for vaccine development and therapy. Lancet Infect Dis 8: 461-471.
43. Gaschen B, Taylor J, Yusim K et al (2002) Diversity considerations in HIV-1 vaccine selection. Science 296: 2354-2360.
44. Esparza J, Osmanvo S (2003) HIV vaccines: a global perspective. Curr Mol Med 3: 183-193.
45. Stratov I, DeRose R, Purcell DF et al (2004) Vaccines and vaccine strategies against HIV. Curr Drug Targets 5: 71-88.